Contrasting of Aptinyx Inc. (APTX) and Proteostasis Therapeutics Inc. (NASDAQ:PTI)

Aptinyx Inc. (NASDAQ:APTX) and Proteostasis Therapeutics Inc. (NASDAQ:PTI) compete with each other in the Biotechnology sector. We will analyze and compare their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aptinyx Inc. 6.72M 27.77 46.41M -1.42 0.00
Proteostasis Therapeutics Inc. 4.46M 43.30 58.36M -1.76 0.00

Table 1 highlights Aptinyx Inc. and Proteostasis Therapeutics Inc.’s top-line revenue, earnings per share and valuation.


Table 2 shows the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Aptinyx Inc. -690.63% 0% 0%
Proteostasis Therapeutics Inc. -1,308.52% -104.1% -76.7%


Aptinyx Inc. has a Current Ratio of 21.8 and a Quick Ratio of 21.8. Competitively, Proteostasis Therapeutics Inc.’s Current Ratio is 4.2 and has 4.2 Quick Ratio. Aptinyx Inc.’s better ability to pay short and long-term obligations than Proteostasis Therapeutics Inc.

Insider and Institutional Ownership

Aptinyx Inc. and Proteostasis Therapeutics Inc. has shares held by institutional investors as follows: 76% and 47.6%. Insiders held roughly 3.9% of Aptinyx Inc.’s shares. Insiders Competitively, held 0.5% of Proteostasis Therapeutics Inc. shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aptinyx Inc. -6.03% -19.01% -34.47% 0% 0% 3.32%
Proteostasis Therapeutics Inc. -6.11% -31.11% 94.29% 60.27% 88.14% -18.35%

For the past year Aptinyx Inc. has 3.32% stronger performance while Proteostasis Therapeutics Inc. has -18.35% weaker performance.


Aptinyx Inc. beats on 9 of the 10 factors Proteostasis Therapeutics Inc.

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. The company is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response (UPR) modulators that are in preclinical development. It has collaboration with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.